Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease

INTRODUCTION: In the cardiovascular outcome trials (CVOT) EMPA-REG OUTCOME, TECOS and SAVOR-TIMI 53, empagliflozin [sodium/glucose cotransporter 2 (SGLT2) inhibitor], sitagliptin and saxagliptin [both dipeptidyl peptidase 4 (DPP4) inhibitors] + standard of care (SoC) were compared to SoC in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos, Mafalda, Foos, Volker, Ustyugova, Anastasia, Hau, Nikco, Gandhi, Pranav, Lamotte, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848565/
https://www.ncbi.nlm.nih.gov/pubmed/31602601
http://dx.doi.org/10.1007/s13300-019-00701-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848565/
https://www.ncbi.nlm.nih.gov/pubmed/31602601
http://dx.doi.org/10.1007/s13300-019-00701-3

Ejemplares similares